---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-144970"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:26:12.272090+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q1 net loss $57.6M; RAS(ON) inhibitors advancing toward clinic

## Summary
- Net loss $57.6M vs $37.2M YoY; revenue $7.6M from Sanofi collaboration (down from $10.2M).
- Cash and securities $518.8M at Mar 31, 2022, down from $577.1M at Dec 31, 2021.
- FY 2022 net loss guidance reaffirmed at $260M-290M, including $35M-40M stock-based comp.
- IND submitted for RMC-6236 (RAS MULTI); first patient dosing mid-2022. RMC-6291 IND on track for H1 2022.
- RMC-4630 Phase 2 combo with sotorasib enrolling; enrollment completion expected H2 2022.

## SEC filing metadata
- accession: 0001193125-22-144970
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/0001193125-22-144970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/d285264d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-144970
- JSON: https://secwatch.observer/filing/0001193125-22-144970.json
- Plain text: https://secwatch.observer/filing/0001193125-22-144970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.